Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Pleased to share our new paper in American Society of Clinical Oncology (ASCO) journal JCO Precision Oncology․
Tumor-agnostic therapies target molecular alterations regardless of histology- transforming care for patients with rare and difficult-to-treat cancers.
Clinical integration remains inconsistent. Why? One reason․ Absence of unified guidelines.
Living guidelines are urgently needed
- Just-in-time evidence incorporation
- Streamlined biomarker-driven care
- Access for rare/ultra rare cancers.”
Title: Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment
Authors: Vivek Subbiah, Thomas K. Oliver, Jim Palma, Razelle Kurzrock
Other Articles Featuring Vivek Subbiah on OncoDaily.